Tiziana Life Sciences – Dr. Howard Weiner has received a competitive research grant from the National Institute of Health (NIH) June 4, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences plc (“Tiziana” or the “Company”) Tiziana Life Sciences announces that its Scientific Advisory Board Chairman Dr. Howard Weiner received NIH grant to investigate Nasal Anti-CD3 for the treatment of Alzheimer’s disease This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. New York/London, 4 June 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious…

Tiziana Life Sciences Plc – Exercise of Warrants and Issue of Equity and Total Voting Rights June 3, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences plc (“Tiziana” or the “Company”) Correction – Exercise of Warrants and Issue of Equity and Total Voting Rights The announcement (RNS Number: 6069O) released on 2 June 2020 at 07:00 am stated that 1,498,685 new ordinary shares will be issued yielding £710,843 in cash proceeds, the announcement should have stated the number of shares to be issued is 1,234,399, yielding £578,700 cash proceeds. All other details in the announcement remain unchanged. The amended announcement is set out below:…

Tiziana Life Sciences #TILS presents StemPrintER, a superior prognostic test compared to Oncotype DX to predict breast cancer May 29, 2020 – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences announces presentation of StemPrintER, a superior prognostic test as compared to Oncotype DX to predict breast cancer · StemPrintER Outperforms Oncotype DX in analysis with 800+ samples from ER+/HER2- postmenopausal breast cancer patients · SPARE Model is up to 40-50% more accurate than standard clinical markers in analysis with 1800+ samples for prediction of distant metastasis New York/London – May 29, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology…

Tiziana Life Sciences #TILS – Demerger of StemPrintER Genomics-Based Personalized Medicine business as a separate listed company May 22, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York and London, May 22, 2020 – Tiziana Life Sciences plc (NASDAQ: TLSA, AIM: TILS), a clinical stage biotechnology company developing targeted drugs for cancer, inflammatory diseases and COVID-19, today announces that it intends to demerge its StemPrintER and SPARE (together “StemPrintER”) genomics-based personalized medicine businesses into a separate company and effect a capital reduction to facilitate the spin-out and listing of StemPrintER as an independent entity. Following the Company’s recent announcement concerning the…

Tiziana Life Sciences – TR1 Notification – Quilter Plc May 21, 2020 – Posted in: Tiziana Life Sciences (TILS)

TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii: Tiziana Life Sciences Plc 1b. Please indicate if the issuer is a non-UK issuer (please mark with an…

Tiziana Life Sciences #TILS – Exercise of Warrants and Issue of Equity May 18, 2020 – Posted in: Tiziana Life Sciences (TILS)

London, New York, 18 May 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (the “Company” or “Tiziana”), a US and UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announces that it has allotted and issued 264,286 ordinary shares of 3 pence each (“New Ordinary Shares”) credited as fully paid in respect of the exercise of 264,286 warrants at…

Tiziana Life Sciences #TILS – Online Publication of Two Abstracts at ASCO Reporting Clinical Activity & Safety of Milciclib in Patients with Advanced Hepatocellular Carcinoma May 14, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York and London, May 14, 2020 – Tiziana Life Sciences plc (NASDAQ: TLSA, AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases , today announces the online publication of two abstracts on clinical studies with Milciclib, a small molecule pan-inhibitor of cyclin dependent kinases (CDKs) in the proceedings of the virtual annual meeting of American Society of Clinical Oncology 2020 (ASCO20) The first abstract…

Alan Green talks markets, Tiziana Life Sciences #TILS, Blue Prism #PRSM & Tertiary Minerals #TYM on UK Investor Mag podcast – Posted in: Tiziana Life Sciences (TILS)

Alan Green discusses markets, Tiziana Life Sciences #TILS, Blue Prism #PRSM & Tertiary Minerals #TYM with Jonathan Roy on the UK Investor Mag podcast. Link on the image to listen.

Tiziana Life Sciences #TILS – ASCO Conference – StemPrintER Study Presentation – Posted in: Tiziana Life Sciences (TILS)

Tiziana Life Sciences Announces Data Demonstrating StemPrintER’s Superiority Compared to OncotypeDX in Providing Prognostic Information to Conventional Clinical Parameters in Breast Cancer Patients in Poster Discussion Session at the American Society of Clinical Oncology (ASCO) Virtual Conference Additional data to be presented validating the SPARE Model for Distant Metastasis Prediction utilizing the Company’s StemPrintER Platform This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. New York/London – May…

Tiziana Life Sciences #TILS to present two studies featuring StemPrintER during the American Society of Clinical Oncology (ASCO) Virtual Conference May 11, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York/London – May 11, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, announces that two abstracts on the Company’s stem cell biology-based genomic tool, StemPrintER, for the prediction of disease recurrence in breast cancer patients, will be presented at the American Society of Clinical Oncology’s 2020 Virtual Conference. All abstracts, including Abstract #1020, which compares Tiziana’s product to…

« First
Previous
1
...
3
4
5
6
7
...
11
Next
Last »